MK 8591

Drug Profile

MK 8591

Alternative Names: 4-ethynyl-2-fluoro-2-deoxyadenosine; EFdA; MK-8591

Latest Information Update: 24 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antiretrovirals
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV-1 infections
  • Preclinical HIV-2 infections

Most Recent Events

  • 04 Mar 2018 Clinical trials in HIV-1 infections (In volunteers) in USA (PO) before March 2018
  • 04 Mar 2018 Pharmacokinetics and adverse events data from a clinical trial in HIV-1 infections presented at the 25th Conference on Retroviruses and Opportunistic Infections (CROI-2018)
  • 27 Nov 2017 Phase-II clinical trials in HIV-1 infections (Treatment-naive, Combination therapy) in USA (PO) (NCT03272347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top